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background:  Despite potent statin therapy, residual risk of CVD events remains unacceptably high. Atherogenic lipoprotein particles and 
subclass distribution on statin therapy may identify markers of residual risk.
Methods:  Among 11,984 participants in JUPITER (NCT00239681; AstraZeneca) with lipoproteins measured by nuclear magnetic 
resonance (NMR; LipoScience) at baseline and 1-year of randomized allocation to rosuvastatin or placebo, we evaluated residual risk 
of CVD (trial primary endpoint) among statin-allocated participants in relation to on-treatment levels of atherogenic particles using Cox 
adjusted models. Risks were compared to placebo-allocated participants.
Results:  After 1-year of rosuvastatin 20 mg daily, each 1-standard deviation (1-SD) higher total VLDL particle concentration (VLDLp), 
and in particular the smallest VLDLp subclass, was strongly associated with residual risk (Table). Further, adjusted HRs (95% CIs) per 
increasing tertile of on-treatment small VLDLp were 1.00 (Ref.), 2.29 (1.09, 4.82), and 3.73 (1.86, 7.49), p for trend <0.0001. For each 
1-SD greater mean VLDL size, reflecting a shift away from small VLDLp, there was a 40% relative risk reduction in residual risk of CVD. By 
contrast, triglycerides and smaller LDL size were not associated with residual risk.
conclusion:  VLDL subclass distribution may be an important predictor of residual risk in patients on potent statin therapy and a potential 
target for therapeutic modulation.
Baseline and residual (on statin-therapy) risk of incident CVD.
Baseline Risk (HR [CI] per SD) p-value Residual Risk (HR [CI] per SD) p-value
Non-HDLc 1.17 (1.01, 1.36) 0.043 1.14 (0.98, 1.34) 0.10
Apolipoprotein B 1.27 (1.09, 1.47) 0.002 1.20 (0.98, 1.46) 0.08
Triglycerides 1.28 (1.11, 1.48) 0.001 0.98 (0.75, 1.28) 0.87
VLDL size 1.10 (0.95, 1.27) 0.22 0.62 (0.47, 0.83) 0.001
Total VLDLp 1.21 (1.04, 1.41) 0.016 1.34 (1.05, 1.71) 0.018
Large VLDLp 1.17 (1.00, 1.37) 0.049 1.03 (0.81, 1.32) 0.79
Medium VLDLp 1.30 (1.10, 1.53) 0.002 1.00 (0.78, 1.28) 0.99
Small VLDLp 1.16 (0.99, 1.36) 0.07 1.68 (1.28, 2.22) 0.0002
VLDL/chylomicron triglycerides 1.24 (1.07, 1.44) 0.004 1.04 (0.82, 1.32) 0.77
